News of Note—Recro and Novartis extend pact

Woman typing on computer
Pacira Pharmaceuticals says that CMDO Thermo Fisher Scientific Pharma Services has started commercial production of its a surgical pain drug Exparel. (Max Pixel CC0)

> Recro Pharma has entered into a five-year manufacturing and supply agreement with Novartis to continue to be the exclusive global supplier of Ritalin LA and Focalin XR capsules through 2023. Release

> Pacira Pharmaceuticals says that CMDO Thermo Fisher Scientific Pharma Services has started commercial production of its a surgical pain drug Exparel at a facility in the U.K. that is expected to double the company’s manufacturing capacity. Release

> Women’s health focused Mithra says it has successfully produced its first commercial batch of vaginal contraceptive Myring for the European market. Release (PDF)

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

 

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.